Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. LFWD
LFWD logo

LFWD Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
6.340
Open
6.340
VWAP
6.24
Vol
11.32K
Mkt Cap
9.64M
Low
6.080
Amount
70.67K
EV/EBITDA(TTM)
--
Total Shares
1.53M
EV
24.97M
EV/OCF(TTM)
--
P/S(TTM)
0.34
Lifeward Ltd, formerly known as ReWalk Robotics Ltd, is a medical device company. The Company is engaged in designing, developing, and commercializing exoskeletons that allow individuals with mobility impairments or other medical conditions the ability to stand and walk again. The Company offers an exoskeleton that uses its tilt-sensor technology and an onboard computer and motion sensors to drive motorized legs that power movement. Lifeward designs are intended for people with paraplegia, a spinal cord injury resulting in complete or incomplete paralysis of the legs, having the use of their upper bodies and arms. The Company offers multiple products: ReWalk Personal, ReStore Exo-Suit, MYOLYN FES Cycling, and AlterG Anti-Gravity Systems. ReWalk Personal is designed for everyday use by paraplegic individuals at home and in their communities and is custom-fitted for each user. Lifeward Rehabilitation products are for use by paraplegia patients in the clinical rehabilitation environment.
Show More

Events Timeline

(ET)
2026-03-25
16:50:00
Lifeward Closes Strategic Partnership with Oramed
select
2026-03-18 (ET)
2026-03-18
08:10:00
Lifeward Reports Q4 Revenue of $5.1M, CEO Highlights Strategic Investment
select
2026-03-13 (ET)
2026-03-13
08:20:00
Lifeward Shareholders Approve Partnership with Oramed
select
2026-03-02 (ET)
2026-03-02
08:30:00
Lifeward Partners with Shirley Ryan AbilityLab for ReWalk Exoskeleton Clinics
select
2026-02-25 (ET)
2026-02-25
08:20:00
Lifeward Acquires Skelable Technology Assets for $480,000
select
2026-02-23 (ET)
2026-02-23
20:00:00
Rewalk Robotics LTD Trading Halted, News Pending
select
2026-02-17 (ET)
2026-02-17
08:20:00
Lifeward Secures Aetna Approval for ReWalk Exoskeleton
select

News

moomoo
7.5
03-25moomoo
LIFEWARD FINALIZES STRATEGIC PARTNERSHIP WITH ORAMED
  • Partnership Announcement: LifeWard has successfully closed a strategic partnership with Oramed Pharmaceuticals.
  • Focus on Innovation: The collaboration aims to enhance the development of innovative therapies, particularly in the field of diabetes treatment.
Yahoo Finance
9.5
03-18Yahoo Finance
Lifeward Ltd Earnings Analysis and Strategic Outlook
  • Strategic Transaction Strengthens Capital Base: Lifeward Ltd's strategic transaction with Oomed provides significant capital access, thereby reinforcing its financial foundation and laying a solid groundwork for future technology platform development.
  • International Market Expansion: The company has made significant progress in international distribution, particularly in Europe, achieving reimbursement coverage for Rewalk with major Medicare insurers, which enhances patient access and strengthens market competitiveness.
  • Revenue Decline Challenges: Despite advancements in technological innovation, the company faced a 14% year-over-year revenue decline, indicating financial challenges, particularly as the hybrid sales model in the U.S. has yet to yield expected revenue growth, impacting overall profitability.
  • Future Growth Potential: Although specific financial guidance is not currently provided, CEO Mark Grant anticipates maximizing reimbursement coverage within the next 12 to 18 months, supported by a promising 22% year-over-year growth in units sold, indicating strong market demand and growth potential.
seekingalpha
9.5
03-18seekingalpha
Lifeward Ltd. Q4 2025 Earnings Call Insights
  • Strategic Transformation: Lifeward is finalizing a partnership with Oramed, expected to provide a $3 million loan and $10 million in convertible note financing upon transaction close, thereby strengthening its financial foundation and driving future innovations.
  • Financial Performance: Revenue for 2025 was $22 million, down approximately 14% from $25.7 million in 2024, although ReWalk unit sales increased by 22% year-over-year, indicating potential market demand growth.
  • Operational Efficiency Gains: Operating expenses decreased by 25% to $28.1 million, with operating loss narrowing by 33% to $19.7 million, reflecting significant progress in cost control that will aid in achieving positive cash flow in the future.
  • Market Outlook: Management did not provide future guidance, emphasizing the significant transformation the company is undergoing; despite analysts expressing concerns about diversification and execution risks, management remains optimistic about long-term growth in its core MedTech business.
seekingalpha
9.5
03-18seekingalpha
Lifeward Reports Q4 2025 Earnings Miss
  • Earnings Report Disappointment: Lifeward's Q4 2025 non-GAAP EPS of -$2.85 missed expectations by $1.77, indicating a significant decline in profitability that could negatively impact investor confidence.
  • Revenue Decline: The company reported revenue of $5.08 million for Q4, a 32.7% year-over-year decrease from $7.5 million in Q4 2024, highlighting overall sales weakness and necessitating a reassessment of market strategies to regain growth.
  • Sales Fluctuations: While revenue from ReWalk personal exoskeletons increased by 20% to $1.8 million, sales of the MyoCycle FES bike plummeted by 90% to $0.1 million, indicating challenges in product portfolio management and the need for enhanced marketing of core products.
  • Stock Price Reaction: Following the earnings report, Lifeward's shares fell by 6%, reflecting market concerns about the company's future prospects, potentially prompting management to consider a 1-for-12 reverse stock split to improve share performance.
seekingalpha
9.5
03-17seekingalpha
Lifeward to Announce Q4 Earnings on March 18
  • Earnings Announcement Date: Lifeward (LFWD) is set to announce its Q4 earnings on March 18 before market open, with a consensus EPS estimate of -$1.08, reflecting a staggering 184.2% year-over-year decline, indicating significant profitability challenges for the company.
  • Revenue Expectations: The consensus revenue estimate stands at $7.87 million, representing a modest 4.2% year-over-year growth, suggesting some market demand that could lay the groundwork for future recovery despite the overall weak performance.
  • Historical Performance Review: Over the past two years, Lifeward has only beaten EPS estimates 13% of the time and revenue estimates 38% of the time, highlighting the company's struggles in achieving profitability and revenue growth, which may impact investor confidence.
  • Stock Split Plan: Lifeward plans to implement a 1-for-12 reverse stock split, aimed at increasing the share price and improving market perception, which could attract more investor attention, but may also raise concerns about the company's financial health.
moomoo
7.5
03-13moomoo
LIFEWARD SECURES SHAREHOLDER CONSENT TO FINALIZE STRATEGIC ALLIANCE WITH ORAMED, FORMING A DIVERSIFIED BIOMEDICAL FIRM
  • Shareholder Approval: LifeWard has received approval from its shareholders to proceed with a strategic partnership.

  • Partnership with Oramed: The partnership involves collaboration with Oramed, focusing on the development of diversified biomedical solutions.

Wall Street analysts forecast LFWD stock price to rise
1 Analyst Rating
Wall Street analysts forecast LFWD stock price to rise
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 0.000
sliders
Low
4.50
Averages
4.50
High
4.50
Current: 0.000
sliders
Low
4.50
Averages
4.50
High
4.50
H.C. Wainwright
NULL -> Buy
maintain
$10
AI Analysis
2026-03-19
Reason
H.C. Wainwright
Price Target
$10
AI Analysis
2026-03-19
maintain
NULL -> Buy
Reason
H.C. Wainwright adjusted the firm's price target on Lifeward to $10 from $4.50 and keeps a Buy rating on the shares. The firm cites the company's 1-12 reverse stock split for the target change.
H.C. Wainwright
Swayampakula Ramakanth
Buy
downgrade
$13
2025-11-18
Reason
H.C. Wainwright
Swayampakula Ramakanth
Price Target
$13
2025-11-18
downgrade
Buy
Reason
H.C. Wainwright analyst Swayampakula Ramakanth lowered the firm's price target on Lifeward to $4.50 from $13 and keeps a Buy rating on the shares following the Q3 report. The firm says the company's operational changes, regulatory wins and changes in payor dynamics underway bode well for future growth.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for LFWD
Unlock Now

Valuation Metrics

The current forward P/E ratio for Lifeward Ltd (LFWD.O) is -1.95, compared to its 5-year average forward P/E of -3.49. For a more detailed relative valuation and DCF analysis to assess Lifeward Ltd's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-3.49
Current PE
-1.95
Overvalued PE
-1.43
Undervalued PE
-5.55

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.56
Undervalued EV/EBITDA
-0.56

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
4.00
Current PS
0.32
Overvalued PS
8.18
Undervalued PS
-0.18

Financials

AI Analysis
Annual
Quarterly

Whales Holding LFWD

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is Lifeward Ltd (LFWD) stock price today?

The current price of LFWD is 6.31 USD — it has decreased -1.87

What is Lifeward Ltd (LFWD)'s business?

Lifeward Ltd, formerly known as ReWalk Robotics Ltd, is a medical device company. The Company is engaged in designing, developing, and commercializing exoskeletons that allow individuals with mobility impairments or other medical conditions the ability to stand and walk again. The Company offers an exoskeleton that uses its tilt-sensor technology and an onboard computer and motion sensors to drive motorized legs that power movement. Lifeward designs are intended for people with paraplegia, a spinal cord injury resulting in complete or incomplete paralysis of the legs, having the use of their upper bodies and arms. The Company offers multiple products: ReWalk Personal, ReStore Exo-Suit, MYOLYN FES Cycling, and AlterG Anti-Gravity Systems. ReWalk Personal is designed for everyday use by paraplegic individuals at home and in their communities and is custom-fitted for each user. Lifeward Rehabilitation products are for use by paraplegia patients in the clinical rehabilitation environment.

What is the price predicton of LFWD Stock?

Wall Street analysts forecast LFWD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for LFWD is4.50 USD with a low forecast of 4.50 USD and a high forecast of 4.50 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Lifeward Ltd (LFWD)'s revenue for the last quarter?

Lifeward Ltd revenue for the last quarter amounts to 5.08M USD, decreased -32.66

What is Lifeward Ltd (LFWD)'s earnings per share (EPS) for the last quarter?

Lifeward Ltd. EPS for the last quarter amounts to -3.59 USD, decreased -82.75

How many employees does Lifeward Ltd (LFWD). have?

Lifeward Ltd (LFWD) has 81 emplpoyees as of March 31 2026.

What is Lifeward Ltd (LFWD) market cap?

Today LFWD has the market capitalization of 9.64M USD.